Rheumatology
Latest News
Bone Infections Increase After S. aureus Bacteremia in Patients With Rheumatoid Arthritis
The 90-day cumulative incidence of osteoarticular infections was nearly double in patients with RA and was higher in those on tumor necrosis...
From the Journals
Tuberculosis Screening Gaps Persist in New DMARD Users
Substantial patient safety gaps regarding latent tuberculosis screening persist among new users of biologic or targeted synthetic DMARDs,...
Feature
Autoimmunity’s Female Bias and the Mysteries of Xist
Researchers are homing in on a long non-coding RNA, essential to X chromosome inactivation, as the culprit in sex-biased autoimmune diseases like...
Conference Coverage
Early Biologic Initiation Linked to Rapid Improvement of JIA, Sustained Remission
The findings have implications for insurance rules that require patients to take a conventional DMARD for a minimum period before initiating...
Latest News
Europe’s Quest for Earlier Diagnosis of Psoriatic Arthritis
European research consortium aims to set forth improved guidelines on PSA biomarkers, diagnostic and monitoring tools, and more.
Latest News
Multiple Social Disadvantages Linked to Progressively Worse JIA and Pediatric Lupus
Children living in disadvantaged areas had higher rates of active disease in JIA and lupus, studies suggest.
Latest News
Anti-Osteoporosis Drugs Found Just as Effective in Seniors
Age is not a significant factor in reducing fracture risk; medications similarly effective in range of ages, finds study.
From the Journals
PT Delivered Via Telemedicine Proves Noninferior to In-Person Care for Chronic Knee Pain
The results are a “game changer” for physical therapy, one expert said, and could help expand access to physiotherapy services for an underserved...
Conference Coverage
RA Outcomes Worsened by Depression and Anxiety, Signaling Need for Multidisciplinary Action
Patients with anxiety or depression were less likely to achieve low disease activity and improve their symptoms compared with those without these...
News from the FDA/CDC
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous Formulations
It’s unclear when the new tocilizumab products will be commercially available.
Conference Coverage
No Increase in Autoimmune Risk Seen With GLP-1 Receptor Agonists and SGLT2 Inhibitors
Patients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease...